ABSTRACT Background. A phase 1b trial was conducted to evaluate the duration of interferon-alpha (IFNa) production after intravesical administration of recombinant adenovirusmediated interferon a2b (Ad-IFN) formulated with the excipient Syn3. The primary aim was to determine whether a second instillation 3 days after initial treatment produced prolonged urinary IFN production. Methods. The study enrolled seven patients who experienced recurrent non-muscle invasive bladder cancer after bacillus Calmette-Guerin therapy. Each treatment consisted of intravesical instillation of SCH721015 (Syn3) and Ad-IFN at a concentration of 3 9 10 11 particles/mL to a total volume of 75 mL given on days 1 and 4. The patients were followed for 12 weeks, during which the magnitude and duration of gene transfer were determined by urine INFa levels. Drug efficacy was determined by cystoscopy and biopsy, and patients who had no recurrence at 12 weeks were eligible for a second course of treatment. Results. Seven patients were treated with an initial course (instillation on days 1 and 4). Two of the patients had a complete response at 12 weeks and received a second course of treatment. One patient remained without evidence of recurrence after a second course (total 24 weeks). One patient experienced a non-treatment-associated adverse event. Despite a transient rise in IFNa levels, sustained production was not demonstrated. Conclusion. Previously, Ad-IFNa intravesical therapy has shown promising drug efficacy. A prior phase 1 trial with a single instillation compared similarly with the current study, suggesting that a second instillation is not necessary to achieve sufficient urinary IFNa levels.
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The American Cancer Society estimates that 74,000 new bladder cancer cases and 16,000 bladder cancer deaths occurred during 2015 in the United States. Therapy in these cases generally consisted of frequent surveillance cystoscopy and resection for Non-Muscle Invasive Bladder Cancer (NMIBC), with the use of intravesical therapy for patients with intermediate-and high-risk NMIBC. Radical cystectomy with or without the addition of systemic chemotherapy generally is reserved for Muscle-Invasive Bladder Cancer (MIBC) and also remains the treatment of choice for high-risk NMIBC refractory to first-line intravesical therapy. Intravesical bacillus Calmette-Guerin (BCG) therapy has proved to be highly effective as primary therapy for high-risk NMIBC, with 5 year recurrence-free survival rates of 60 % achieved with maintenance therapy. 1 Unfortunately, this leaves a substantial minority of NMIBC patients who go on to fail BCG therapy in an era with only modestly effective second-line intravesical therapies. 2 In fact, NMIBC response rates are so poor after BCG failure that the most recent European Association of Urology guidelines state that ''treatments other than radical cystectomy must be considered oncologically inferior at Neema Navai and William F. Benedict contributed equally to this paper.
the present time''. 3 Despite these recommendations, patients and clinicians are frequently challenged by patient factors including severe medical comorbidities and reluctance to undergo radical cystectomy, in no small measure due to the high complication rate 4 in the perioperative setting. For this reason, much interest has remained focused on the development of novel second-line intravesical therapies for refractory NMIBC.
Among the most promising treatments have been novel immunologic therapies directed at enhancing the native immune response in the bladder. Our previous phase 1 trial evaluated gene therapy via adenovirus-mediated recombinant interferon alpha 2b (Ad-IFNa) formulated with the excipient SCH 209702 (Syn3), an agent that enhances gene transfer. 5 Through both direct and indirect cellular mechanisms, Ad-IFNa has shown preclinical activity against malignant cells while sparing normal urothelium.
The primary aim of the phase 1 trial was drug safety after a single instillation in patients with recurrent NMIBC after initial BCG plus maintenance therapy. Notably, no dose-limiting toxicity was encountered despite a doseescalation design. Additionally, clinical efficacy at 3 months demonstrated a complete response rate of 43 % 5 despite a return of urinary IFNa levels to baseline levels in the majority of patients by 10 days after treatment. 5 In preparation for a phase 2 study, we aimed to determine whether additional intravesical instillations of Ad-IFNa could produce sustained IFNa production and possibly improve clinical efficacy.
In an orthotopic mouse model of human bladder cancer, a second instillation of intravesical Ad-IFN/Syn3 treatment produced a twofold increase in urine IFNa levels (100,000 vs. 50,000 pg/mg) with associated prolonged INFa elevations. 6 To aid in dose scheduling for a planned phase 2 trial, we conducted a phase 1b trial involving two instillations of Ad-IFNa/Syn3 in patients with recurrent NMIBC. We hypothesized that a second instillation would result in increased and prolonged IFNa production.
MATERIALS AND METHODS

Eligibility and Objectives
This study was a single-institution, single-arm, phase 1b trial. Patients with NMIBC refractory to BCG therapy who refused radical cystectomy were considered eligible for inclusion in the trial. In this trial, BCG-refractory NMIBC was defined as recurrence or persistence of BT1 bladder cancer after treatment with a 6 week induction course and at least one additional course of BCG (either a 3 week maintenance course or a repeat 6 week induction course). Additional study entry requirements remained unchanged from the phase 1 trial. 5 The study was approved by the University of Texas MD Anderson Cancer Center institutional review board.
The primary study end point was to determine whether a second instillation of the study drug on day 4 improved gene transfer efficacy, as determined by the magnitude and duration of urinary INFa. Secondarily, complete response (CR), defined as lack of tumor recurrence 3 months after treatment, was evaluated.
Treatment
As previously published, patients underwent intravesical treatment with Ad-IFNa constituted in the excipient Syn3. 5 The results of the prior trial determined the optimal concentration of Ad-IFNa to be 3 9 10 11 particles per milliliter. A total volume of 75 mL was constituted in a solution of Syn3 at a 1-mg/mL concentration. Instillations, administered days 1 and 4 on an outpatient basis, were allowed to dwell for 1 h. Complete responders were allowed a second treatment cycle 3 months after the initial treatment.
Evaluation of Gene Transfer Efficacy
Urine samples were obtained before treatment and for 14 days after the initial treatment dose. Urine IFNa concentrations were determined for samples collected on ice and stabilized by the addition of buffer containing 10 % bovine serum albumin and 50 mmol of HEPES (4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid: 1 mL of buffer to 10 mL of urine). Levels of IFNa were determined by enzyme-linked immunosorbent assay (ELISA) from R&D Systems Inc. (Minneapolis, MN) using the manufacturer's protocol with the extended range standard curve as previously described. 5 
RESULTS
Clinical Outcomes
This trial enrolled seven patients, who underwent protocol treatment. Salient clinical, pathologic, and demographic features are summarized in Table 1 . All the patients were men with a mean age of 77 years (range 68-83 years) at the onset of treatment. One patient (patient 1) withdrew 7 weeks after treatment due to worsening lower urinary tract symptoms, and he represents the only adverse event in the study.
Two (29 %) of the seven patients (patients 4 and 7) had a CR at 3 months and were eligible for a second treatment cycle. Two of the seven patients had CRs after treatment cycles, for an overall clinical efficacy of 29 %.
One patient with T1 high-grade disease at enrollment achieved a 3 month CR and remained disease free after the second treatment cycle (180 days after initial enrollment). After completion of the study, all the patients continued to receive care at our center, and during prolonged follow-up evaluation, all eventually had disease recurrence and were recommended to undergo radical cystectomy. One patient (patient 6) refused radical cystectomy and was lost to follow-up evaluation Of the remaining six patients, five had organ-confined, lymph-node-negative disease at cystectomy and remain disease free at this writing. Patient 1 was found to have non-organ-confined disease with multiple positive lymph nodes at radical cystectomy. He succumbed to disease 20.1 months after study treatment and 16.7 months after radical cystectomy. The median followup period was 29.4 months (range 20.1-36.0 months) from day 1 of treatment to the last confirmed contact with each patient.
Urinary IFNa Levels
The urinary IFNa levels over time are summarized in Fig. 1a for all instances, including the retreatments of patients 4 and 7. Three patients demonstrated transient secondary peaks in urinary INFa after the second instillation and are highlighted in Fig. 1b . Despite these second peaks, sustained IFNa levels were not demonstrated, and all the patients returned to baseline levels by day 10.
DISCUSSION
Bladder cancer is a common malignancy hallmarked by recurrences of NMIBC and, frequently, by life-threatening disease in MIBC. Although intravesical BCG remains the gold standard treatment for initial high-risk NMIBC, recurrent/refractory NMIBC poses a clinical challenge. The high response rates of nearly 70 % 7 seen for patients treated with BCG for primary carcinoma in situ (CIS) far overshadow those for second-line therapies. 2, 7, 8, 11 For this reason, radical cystectomy remains the treatment of choice for eligible patients with recurrent NMIBC after optimized intravesical BCG therapy.
Patients, however, are frequently reluctant to undergo extirpative surgery and not without cause. Radical cystectomy is notable for an overall complication rate of 64 % and a high-grade complication rate of 13 %. 12 Additionally, 30 day mortality rates range from 1.5 to 3 %, 12, 13 and when the impact of urinary diversion, the major source of T  D13  D12  D11  D10  D9  D8  D7  D6  D5  D4  D3  D2  D1  Pre-T   D13  D12  D11  D10  D9  D8  D7  D6  D5  D4  D3  D2  D1  Pre-T   FIG. 1 Urinary interferon-alpha (IFNa) levels. a Urine IFNa levels in all seven patients at various times after intravesical treatment on days 1 and 4. b Urine IFNa levels in individual patients who showed an increase in IFNa after the day 4 retreatment complications after radical cystectomy, 4 is added to this, it is not difficult to see why patients commonly seek secondline therapies despite inferior oncologic outcomes.
To address this clinical need, novel second-line agents for NMIBC are desperately needed. Numerous groups have focused these efforts primarily on cytotoxic intravesical chemotherapies. Unfortunately, chemotherapeutics are well established as inferior to BCG for the primary therapy of NMIBC.
14 Worse still are the results of intravesical chemotherapy as second-line therapy, as demonstrated by the 1 year recurrence-free survival rate of 21 % seen in a phase 2 trial of gemcitabine with patients who had recurrent NMIBC after BCG therapy. 11 More promising results are achievable with the addition of heated chemotherapy, as in the case of mitomycin-c thermochemotherapy. However, recurrence-free rates remain low, at 56 %. 15 One fact remains: the most effective intravesical therapy for NMIBC is BCG, an immune-modulating therapy.
We have shown that Ad-IFNa acts through both direct and indirect mechanisms to produce cell death, which implies that Ad-INFa can cause tumor cell death by other mechanisms, including the production of bystander factors killing tumor cells beyond immunomodulation and the IFNa produced. We therefore developed the novel therapeutic Ad-IFNa/Syn3 to effect gene transfer within the bladder and exploit these mechanisms of tumor cell kill against NMIBC.
Our first human trial using the aforementioned gene therapy produced promising results and a favorable toxicity profile. In this study, a 43 % CR at 3 months in a patient population enriched for resistant disease was found, namely, those who had failed prior intravesical BCG plus maintenance therapy. 5 Additionally, despite dose escalation, no dose-limiting toxicities were encountered. 5 With promising clinical efficacy and minimal side effects, we are currently planning a larger multi-institutional phase 2 trial. To inform better on the optimal dosing strategy for this trial, we sought in the current study to elucidate whether a second instillation of Ad-IFNa/Syn3 on day 4 of the treatment cycle provided an advantage over a single treatment or not. This was informed by preclinical animal studies in which a second instillation did result in prolongation of IFNa production.
Our published preclinical data demonstrated prolonged, robust IFNa production with added instillations of AdIFNa/Syn3 in an orthotopic mouse model. 6 In that study, a second instillation improved IFNa levels twofold (from 50,000 to 100,000 pg/mL) and resulted in sustained production with IFNa levels for 7 days, the full duration of the analysis. However, in the designing of the phase 1 trial, a single instillation was used in an effort to limit the potential for toxicity. Although we were encouraged by the clinical activity in that study, we hypothesized that treating with two instillations rather than one could increase the amount and duration of IFNa production. As a result, we conducted the current study to determine whether IFNa levels analogous to our preclinical experience could be achieved. If so, this would serve as the basis for the treatment schedule Intravesical nanopartical albumin-bound paclitaxel
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Ad-INFa Adenovirus-mediated interferon-alpha Phase 1b Trial of Adenoviral IFNa2b After BCG Failureused in the planned phase 2 trial. Despite a small patient population, the data suggested no improvement across all participants, so we concluded the study after the enrollment and analysis of seven patients. Our study size fell in line with analogous small patient populations for other phase 1 studies (Table 2) with BCG-refractory NMIBC. Nonetheless, these data support the design and implementation of a future single-instillation phase 2 study and reinforce the potential for significant clinical activity after even transient gene transfer and expression.
CONCLUSION
As a novel gene therapy, Ad-IFNa/Syn3 is used for recurrent BCG-resistant NMIBC. The short-term clinical activity is promising, and two instillations versus one does not improve the efficacy of the significantly changed overall IFNa levels produced.
